Apply Emerging Biomarkers to Improve Neurodegenerative Disease Trials
Earn a Certificate of Live Attendance
AI Webinar Explorer available after event
About this webinar
For neurodegenerative disease clinical trials, understanding how a condition is progressing and whether a treatment is having an effect can be difficult using traditional assessments alone. Biomarker science, digital health technologies and precision medicine are creating new ways to capture objective measures of disease. As the prevalence of neurodegenerative conditions continues to grow, there is an increasing need for innovative tools to detect disease, strengthen clinical trial design and support the development of new therapies. This webinar explores how emerging biomarker strategies can help address these challenges across clinical research and therapeutic development.
Biological and imaging biomarkers, together with digital and wearable technologies, are enabling researchers to detect disease earlier, characterize patient populations more accurately, track disease progression and assess treatment response with greater precision. These objective, actionable measures can help inform decision-making across the drug development process.
The featured panelists will examine how biological, digital and wearable markers are being applied across neurodegenerative disease research. Attendees will learn how these approaches can support more efficient clinical trials, strengthen patient selection, enable more personalized treatment strategies and contribute to the development of next-generation therapies.
The session will also examine real-world applications, practical implementation considerations and emerging trends influencing the future of CNS research. Attendees will gain insight into both the opportunities and challenges of incorporating innovative biomarker strategies into research programs and clinical development initiatives. As neurodegenerative disease research becomes increasingly precise, data-driven and patient-centered, biomarkers and digital technologies will play an important role in advancing new treatments and improving patient outcomes.
Register for this webinar to learn how biomarker strategies can advance neurodegenerative disease research and support more precise, data-driven clinical trials.
Who should attend
- Clinical Development leaders
- Clinical Research Scientists
- Neuroscience/CNS Researchers
- Biomarker Scientists
- Translational Medicine Scientists
- Digital Health leaders
What you will learn
- How biological, digital, imaging and wearable biomarkers can support earlier detection and more precise assessment of neurodegenerative diseases
- How biomarker data can strengthen patient selection, clinical trial design and development of more personalized therapies
- How digital health technologies and wearable devices can monitor disease progression and treatment response
- Key considerations and evolving trends influencing biomarker-driven CNS drug development and precision medicine
Featured Speakers
Bob Dagher
Dr. Bob Dagher has more than 20 years of leadership across clinical development, medical affairs and regulatory strategy in neuropsychiatry, neuroimmunology and rare disease. He has served as Chief Medical Officer at four biotech companies, leading programs from first-in-human through Phase III trials and BLA submission across mood disorders, psychotic disorders, neurodegeneration, ALS, MS and rare CNS diseases. Trained in psychiatry at Boston University Medical Center, he holds his MD from Bordeaux University and St. Joseph University School of Medicine.
As Chief Medical Officer at Clinilabs, Dr. Dagher brings a distinguished record of leading scientifically complex CNS drug development programs from first-in-human studies through Phase III trials and regulatory submission, precisely the full-development continuum that defines Clinilabs’ mission as the industry’s leading neurotherapeutic CRO, helping sponsor partners accelerate their CNS programs with the precision, integrity and CNS depth that only Clinilabs delivers.
Nicklas Linz
Nicklas Linz, PhD, is the Co-Founder and CEO of ki:elements, a company pioneering speech-based digital biomarkers for neurological and psychiatric conditions. Dr. Linz leads a multidisciplinary team translating cutting-edge research into scalable health solutions to reshape how clinical trials are designed, measured and conducted.
Chiara Capra
Chiara Capra is the Head of Product Management at Sense4Care. Graduated with a BSc (Hons) in Psychology and an MSc in Neuroscience and Cognitive Neuroscience from King’s College London, Chiara holds extensive experience in the digital healthcare industry, working in Italy, Australia, the UK, South Africa and Spain, where she led projects and product development at an international level on medical devices, telemedicine and digital cloud platforms for therapeutic follow-up.
She graduated from Audacity in Product Management and continues her training at the Massachusetts Institutes of Technology (MIT) Sloan School of Management, where she is currently enrolled in a blockchain course for business innovation and implementation. She is passionate and highly driven by technology innovation in the healthcare field.
Her ultimate aim is to integrate clinical research with technological industry achievements to translate it in the healthcare field and develop innovative solutions for health data management.
Partner for this event
Clinilabs
Clinilabs is a global, full-service clinical research organization (CRO) focused exclusively on central nervous system (CNS) drug, device, and technology development. Drawing on deep, indication-level expertise, a proven process, and the latest technology, we expertly manage Phase 1-3 trials to accelerate treatments for a range of psychiatric, neurological, and substance use disorders, as well as rare and ultra-rare CNS disorders. With 25+ years of global experience, over 800 CNS clinical trial awards completed, and over 30+ marketed products across more than 25 indications, we are the industry’s leading neurotherapeutic clinical trial experts.